Beam Therapeutics Inc (BEAM) Stock Price, Quote & News

Company Profile

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, a...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 327 8775

Website: beamtx.com

Address:

238 Main Street, Cambridge, United States

Elamenape2 Dec. 4 at 5:00 PM

$PRME Amazing to see our better half, $BEAM has essentially recovered. Prime time next!

0 · Reply

EingeLTrade Dec. 4 at 2:35 PM

Oh god 😮😯🤑 $BEAM

1 · Reply

Iightning Dec. 4 at 5:58 AM

1ightning® Premium Options Alert (Actionable) Ticker: $BEAM Contract: Dec 19 $27C Entry: 2.10 Exit: 3.75 Return: +78.37% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Buraku Dec. 4 at 12:49 AM

$BEAM isn’t there some big data conference coming up where they share clinical trials everyone has been expecting to be blockbuster or has that passed

0 · Reply

THE_Monkey_Banana_Genius Dec. 3 at 8:14 PM

$CRSP $BEAM showing some spunk today. Long

1 · Reply

Buraku Dec. 3 at 7:33 PM

$BEAM $CAPR what happens with good clinical news.

0 · Reply

Godwins26 Dec. 3 at 6:29 PM

3rd Watchlist today 😊 $PLRZ $ARWR $MAZE $BEAM $IMNM

0 · Reply

deucestwits Dec. 3 at 5:00 PM

$BEAM nice candle on beam.. was hoping to readd more around 18..

0 · Reply

dbr_island Dec. 3 at 4:17 PM

$SERV breaking $10 was HUGE Been pounding the table from the $4’s $EPOW just received a $30M contract AH 🚨👇🚨👇 That is HUGE for a tiny company This should be at least $2 🎯✅ I’m even willing to put some of my TSLA COIN profits into EPOW👇💰💰💰 $BEAM $MAGH $IRBT let’s go

0 · Reply

Estimize Dec. 3 at 11:00 AM

Wall St is expecting -1.15 EPS for $BEAM Q4 [Reporting 03/03 BMO] http://www.estimize.com/intro/beam?chart=historical&metric_name=eps&utm_c

0 · Reply

Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference

Nov 4, 2025, 7:00 AM EST - 4 weeks ago

Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

Nov 3, 2025, 9:00 AM EST - 4 weeks ago

Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Oct 22, 2025, 10:19 AM EDT - 6 weeks ago

Beam Therapeutics: SCD Catalysts Have Untapped Upside Potential

Sep 9, 2025, 9:54 AM EDT - 3 months ago

Beam Therapeutics Inc. (BEAM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Sep 9, 2025, 4:51 AM EDT - 3 months ago

Beam Therapeutics Inc. (BEAM) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 3, 2025, 8:38 PM EDT - 3 months ago

Beam Therapeutics Inc. (BEAM) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 25, 2025, 7:00 AM EDT - 3 months ago

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

Aug 14, 2025, 7:00 AM EDT - 4 months ago

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

Aug 5, 2025, 7:00 AM EDT - 4 months ago

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

Jun 28, 2025, 9:10 AM EDT - 5 months ago

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

CERT INSP KRYS LFMD OPCH PODD TEM

Jun 20, 2025, 10:07 AM EDT - 5 months ago

Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases

Jun 13, 2025, 7:00 AM EDT - 6 months ago

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

Jun 3, 2025, 7:00 AM EDT - 6 months ago

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

May 29, 2025, 4:01 PM EDT - 6 months ago

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 14, 2025, 9:30 AM EDT - 7 months ago

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

May 13, 2025, 7:00 AM EDT - 7 months ago

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

May 12, 2025, 4:01 PM EDT - 7 months ago

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 6, 2025, 5:05 PM EDT - 7 months ago

Why Beam Therapeutics Stock Tanked on Tuesday

May 6, 2025, 7:00 AM EDT - 7 months ago

Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Apr 5, 2025, 7:00 AM EDT - 8 months ago

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

Mar 31, 2025, 2:25 PM EDT - 8 months ago

Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard

MRNA

Mar 27, 2025, 4:01 PM EDT - 8 months ago

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

Mar 21, 2025, 1:13 PM EDT - 9 months ago

Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy

Mar 10, 2025, 9:07 AM EDT - 9 months ago

Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity

Mar 10, 2025, 6:01 AM EDT - 9 months ago

Beam Therapeutics Announces Pricing of Underwritten Offering

Mar 10, 2025, 6:00 AM EDT - 9 months ago

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

Feb 25, 2025, 7:00 AM EST - 10 months ago

Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

Feb 24, 2025, 7:00 AM EST - 10 months ago

Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

Jan 30, 2025, 7:00 AM EST - 11 months ago

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

Jan 23, 2025, 7:00 AM EST - 11 months ago

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

Jan 13, 2025, 7:00 AM EST - 11 months ago

Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

Dec 8, 2024, 1:45 PM EST - 1 year ago

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

Dec 7, 2024, 11:30 AM EST - 1 year ago

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Dec 6, 2024, 7:00 AM EST - 1 year ago

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

Dec 4, 2024, 7:00 AM EST - 1 year ago

Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

Nov 12, 2024, 4:01 PM EST - 1 year ago

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference

Nov 7, 2024, 2:25 PM EST - 1 year ago

Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch

Nov 5, 2024, 11:54 AM EST - 1 year ago

Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 6:30 AM EST - 1 year ago

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

Oct 29, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

Aug 6, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results

Jul 15, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Announces Transition of Chief Financial Officer

Jun 26, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)

Jun 14, 2024, 3:00 AM EDT - 1 year ago

Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

May 30, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics to Participate in Jefferies Global Healthcare Conference

May 14, 2024, 4:00 PM EDT - 1 year ago

Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress

May 8, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference

May 7, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results

Mar 26, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Elamenape2 Dec. 4 at 5:00 PM

$PRME Amazing to see our better half, $BEAM has essentially recovered. Prime time next!

0 · Reply

EingeLTrade Dec. 4 at 2:35 PM

Oh god 😮😯🤑 $BEAM

1 · Reply

Iightning Dec. 4 at 5:58 AM

1ightning® Premium Options Alert (Actionable) Ticker: $BEAM Contract: Dec 19 $27C Entry: 2.10 Exit: 3.75 Return: +78.37% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Buraku Dec. 4 at 12:49 AM

$BEAM isn’t there some big data conference coming up where they share clinical trials everyone has been expecting to be blockbuster or has that passed

0 · Reply

THE_Monkey_Banana_Genius Dec. 3 at 8:14 PM

$CRSP $BEAM showing some spunk today. Long

1 · Reply

Buraku Dec. 3 at 7:33 PM

$BEAM $CAPR what happens with good clinical news.

0 · Reply

Godwins26 Dec. 3 at 6:29 PM

3rd Watchlist today 😊 $PLRZ $ARWR $MAZE $BEAM $IMNM

0 · Reply

deucestwits Dec. 3 at 5:00 PM

$BEAM nice candle on beam.. was hoping to readd more around 18..

0 · Reply

dbr_island Dec. 3 at 4:17 PM

0 · Reply

Estimize Dec. 3 at 11:00 AM

Wall St is expecting -1.15 EPS for $BEAM Q4 [Reporting 03/03 BMO] http://www.estimize.com/intro/beam?chart=historical&metric_name=eps&utm_c

0 · Reply

Iightning Dec. 3 at 9:53 AM

1ightning® Premium Options Alert (Actionable) Ticker: $BEAM Contract: Dec 19 $14C Entry: 10.75 Exit: 17.30 Return: +60.89% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

LiquidThetaOptions Dec. 2 at 4:40 PM

💎 LiquidTheta® Live Actionable Trade Asset: $BEAM Contracts: $BEAM January 15, 2027 $25 Calls Scale in: $7.88- $9.62 Scale out: $30.62-$52.50 Profit Potential : 203% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

Iightning Dec. 2 at 12:14 AM

**1ightning® Premium Options Alert (Actionable)** **Ticker:** $BEAM **Contract:** Dec 19 $25C **Entry:** 1.60 **Exit:** 2.05 **Return:** **+27.99% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**

0 · Reply

HedgeAlerts Dec. 1 at 10:08 PM

Hedge Alert Live - Protect Your Portfolio Contract: $BEAM $24.00 Put · DEC 19, 2025 Exp Entry Price: $1.50 - $1.75 Exit Price Target: $3.17 Profit Margin: +111% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

RocroBio Nov. 29 at 10:47 PM

$NTLA $PRME $BEAM $CRBU

0 · Reply

Iightning Nov. 26 at 3:06 AM

1ightning® Options Trade Alert (Actionable) | Buy $BEAM Dec 19 $24 Call | Enter: $1.77 Exit: $2.18 | Profit: 23.03% ROI | https://1ightning.com

0 · Reply

HedgeAlerts Nov. 26 at 2:23 AM

Hedge Alert Live - Protect Your Portfolio Contract: $BEAM $24.00 Put · DEC 19, 2025 Exp Entry Price: $1.45 - $1.75 Exit Price Target: $3.35 Profit Margin: +131% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

RunnerSignals Nov. 25 at 8:28 PM

$BEAM $CLSK $LCTX $ADAG Only for traders who like upside with a splash of science https://stocksrunner.com/news/2025-11-25-stock-upgrades-today-see-wall-street-boost-confidence

0 · Reply

LiquidThetaOptions Nov. 25 at 6:33 PM

💎 LiquidTheta® Live Actionable Trade Asset: $BEAM Contracts: $BEAM January 15, 2027 $25 Calls Scale in: $7.38- $9.02 Scale out: $28.70-$49.20 Profit Potential : 283% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

Iightning Nov. 25 at 1:10 PM

1ightning® Options Trade Alert (Actionable) | Buy $BEAM Dec 19 $24 Call | Enter: $1.77 Exit: $2.18 | Profit: 23.03% ROI | https://1ightning.com

0 · Reply

HedgeAlerts Nov. 25 at 2:24 AM

Hedge Alert Live - Protect Your Portfolio Contract: $BEAM $23.00 Put · DEC 19, 2025 Exp Entry Price: $1.65 - $1.70 Exit Price Target: $3.54 Profit Margin: +108% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Iightning Nov. 25 at 2:05 AM

1ightning® Options Trade Alert (Actionable) | Buy $BEAM Dec 19 $24 Call | Enter: $1.77 Exit: $2.18 | Profit: 23.03% ROI | https://1ightning.com

0 · Reply

Market Cap	2.37B
Revenue (ttm)	63.52M
Net Income (ttm)	-376.74M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-593.10%
Debt to Equity Ratio	0.00

Volume	2,662,500
Avg Vol	2,340,822
Day's Range	N/A - N/A
Shares Out	101.48M
Stochastic %K	98%
Beta	2.21
Analysts	Strong Sell
Price Target	$45.93